Skip to main content
SpringerLink
Log in

Androgen Receptor Mutations in Prostate Cancer

  • Chapter
Book cover Drug Resistance

Part of the book series: Cancer Treatment and Research ((CTAR,volume 87))

Abstract

The incidence of prostate cancer in the United States has risen steadily during the past 10 years. This is due to a combination of factors, including increased use of prostate-specific antigen (PSA) for screening, aging of the population, declining mortality from other causes such as cardiac disease, and environmental and dietary factors that have contributed to prostate carcinogenesis. In 1995 it was estimated that 244,000 new cases of prostate cancer would be diagnosed in the United States and prostate cancer would account for approximately 40,400 deaths in that year [1]. The magnitude of the prostate cancer problem has focused attention on the need for better therapies and effective prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wingo PR, Tong T, Bolden S (1995) Cancer statistics, 1995. CA Cancer J Clin 45:8–30.

    Article  PubMed  CAS  Google Scholar 

  2. Griffin JE (1992) Androgen resistance—the clinical and molecular spectrum. N Engl J Med 326:611–618.

    Article  PubMed  CAS  Google Scholar 

  3. Kyprianou N, Isaacs JT (1988) Activation of programmed cell death in the rat ventral prostrate after castration. Endocrinology 122:552–562.

    Article  PubMed  CAS  Google Scholar 

  4. Deaver JB (1922) Enlargement of the prostate: Its history, anatomy, etiology, pathology, clinical causes, symtpoms diagnosis, prognosis, treatment, technique of operations and after-treatment.

    Google Scholar 

  5. Pollard M, Luckert PH (1986) Production of autochthonous prostate cancer in Lobund-Wistar rats: By treatments with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst 77:583–587.

    PubMed  CAS  Google Scholar 

  6. Pollard M, Luckert PH (1987) Autochthonous prostate cancer in Lobund-Wistar rats: A model system. Prostate 11:219–227.

    Article  PubMed  CAS  Google Scholar 

  7. Ghanadian R, Puah CM, O’Donoghue EPN (1979) Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 39:696–699.

    Article  PubMed  CAS  Google Scholar 

  8. Ahluwalia B, Jackson MA, Jones GW, et al. (1981) Blood hormone profiles in prostate cancer patients in high risk and low risk populations. Cancer 48:2267–2273.

    Article  PubMed  CAS  Google Scholar 

  9. Drafta D, Proca E, Zamfir V, et al. (1982) Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 17:689–693.

    Article  PubMed  CAS  Google Scholar 

  10. Zumoff B, Levin J, Strain GW, et al. (1985) Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a “two-disease” theory. Prostate 3:579–588.

    Article  Google Scholar 

  11. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL (1988) Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48:3515–3517.

    PubMed  CAS  Google Scholar 

  12. Huggins C, Hodges CV (1941) Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297.

    CAS  Google Scholar 

  13. Huggins C, Stevens RE, Hodges CL (1941) Studies on prostatic cancer II. The effect of castration on clinical patients with carcinoma of the prostate. Arch Surg 43:209.

    CAS  Google Scholar 

  14. Fisher B, Redmond C, Brown A and NSABP investigators (1983) Influences of tumor estrogen and progesterone receptor levels on the responses to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227–241.

    PubMed  CAS  Google Scholar 

  15. Sadi MV, Walsh PC, Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Cancer 67:3057–3064.

    Article  PubMed  CAS  Google Scholar 

  16. Trachtenberg J, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466.

    PubMed  CAS  Google Scholar 

  17. Gonor SE, Lakey WH, McBlain WA (1984) Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 131:1196.

    PubMed  CAS  Google Scholar 

  18. Benson RC, Gorman PA, O’Brien PC, Holicky EL, Veneziale CM (1987) Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 59:1599.

    Article  PubMed  Google Scholar 

  19. Rennie PS, Bruchovsky N, Goldenberg SL (1988) Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 11(Suppl 2):S13.

    Article  PubMed  Google Scholar 

  20. Castellanos JM, Galan A, Calvo MA, Schwartz S (1982) Predicting response of prostatic cancer to endocrine therapy. Lancet 1:448.

    Article  PubMed  CAS  Google Scholar 

  21. Prout GR (1976) Endocrine changes after diethylstilbestrol therapy: Effect on prostatic neoplasm and pituitary gonadal axis. Urology 7:148.

    Article  PubMed  CAS  Google Scholar 

  22. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281–1286.

    Article  Google Scholar 

  23. Labrie F, Dupong A, Belanger A, et al. (1983) New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 4:579–594.

    Article  PubMed  CAS  Google Scholar 

  24. Crawford ED, Eisenberger M, McCleod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424.

    Article  PubMed  CAS  Google Scholar 

  25. Iversen P, Christensen MG, Friis E, Hornbil P, Hvidt V, Iversen HG, Klaskov P, et al. (1990) A phase III trial of Zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66(Suppl):1058–1066.

    PubMed  CAS  Google Scholar 

  26. Newling D, Pavone Macaluse M, Smith P, de Voogt HJ, Robinson MR, Schroder FH, Denis L, Sylveser R (1992) Update of EORTC clinical trials in prostate cancer. The EORTC Genitourinary Group. Semin Urol 10:65–71.

    PubMed  CAS  Google Scholar 

  27. van Tinteren H, Dalesio O (1993) Systemic overview (metaanalysis) of all randomized trials of treatment of prostate cancer. Cancer 72:3847–3850.

    Article  PubMed  Google Scholar 

  28. Soloway MS, Sharifi R, Wood D, Wajsman Z, McLeod D, Puras A (1995) Randomized comparison of radical prostatectomy alone or preceded by androgen deprivation for cT2b prostate cancer. Proc Am Soc Clin Oncol 14:abstract 644.

    Google Scholar 

  29. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A (1995) Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (report of RTOG protocol 85–31). Proc Am Soc Clin Oncol 14:abstract 631.

    Google Scholar 

  30. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336.

    Article  PubMed  CAS  Google Scholar 

  31. Miyashita T, Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151–157.

    PubMed  CAS  Google Scholar 

  32. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J (199•) Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. SI-MEDL/93373309. Cancer Res 53:••-••.

    Google Scholar 

  33. Berchem G, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP (1995) Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55:735–738.

    PubMed  CAS  Google Scholar 

  34. Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French FS, Willard HF (1989) Androgen receptor locus on the human X chromosome: Regional localization to Xq11–12 and description of a DNA polymorphism. Am J Hum Genet 44:264–269.

    PubMed  CAS  Google Scholar 

  35. Wilding G, Chen M, Gelmann EP (1989) Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103–115.

    Article  PubMed  CAS  Google Scholar 

  36. Veldscholte J, Ris-Stalper C, Kuiper GGJM (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173:534–540.

    Article  PubMed  CAS  Google Scholar 

  37. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572.

    PubMed  CAS  Google Scholar 

  38. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889–895.

    Article  PubMed  CAS  Google Scholar 

  39. O’Malley B (1990) The steroid receptor superfamily: More excitement predicted for the future. Mol Endocrinol 4:363–369.

    Article  PubMed  Google Scholar 

  40. Wahli W, Martinez E (1991) Superfamily of steroid nuclear receptors: Positive and negative regulators of gene expression. FASEB J 5:2243–2249.

    PubMed  CAS  Google Scholar 

  41. Kuiper GGJM, Faber TW, van Rooij HC, van der Korput JA, Ris-Stalpers C, Klaassen P, Trapman J, Brinkmann AO (1989) Structural organization of the human androgen receptor gene. J Mol Endoc 2:R1–R4.

    Article  CAS  Google Scholar 

  42. Lubahn DB, Joseph DR, Sarrinol M, Tan J, Higgs H, Larson RE, French FS, Wilson EM (1988) The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 2:1265–1275.

    Article  PubMed  CAS  Google Scholar 

  43. Trapman J, Klaasen P, Kuiper GJ (1988) Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 153:241–248.

    Article  PubMed  CAS  Google Scholar 

  44. Luisi BF, Xu WX, Otwinowski Z (1991) Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352:497–505.

    Article  PubMed  CAS  Google Scholar 

  45. Hard T, Kellenbach E, Boelens R (1990) Solution structure of the glucocorticoid receptor DNA-binding domain. Science 249:157–160.

    Article  PubMed  CAS  Google Scholar 

  46. Ekman P, Snochowski M, Zetterberg A, Hogberg B, Gustafsson JA (1979) Steroid receptor content in human prostatic carcinoma and response to endocrine therapy. Cancer 44:1173.

    Article  PubMed  CAS  Google Scholar 

  47. Fentie DD, Lakey WH, McBlain WA (1986) Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma. J Urol 135:167.

    PubMed  CAS  Google Scholar 

  48. Takeda H, Chodak G, Mutchnik S, Nakamoto T, Chang C (1990) Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor. J Endocrinol 126:17.

    Article  PubMed  CAS  Google Scholar 

  49. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic, and neoplastic human prostate. J Urol 147:798–803.

    PubMed  CAS  Google Scholar 

  50. Jenster G, van der Korput HAGM, van Vroonhoven C (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation and subcellular localization. Mol Endocrinol 5:1396–1404.

    Article  PubMed  CAS  Google Scholar 

  51. Simental JA, Sar M, Lane MV (1991) Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266:510–518.

    PubMed  CAS  Google Scholar 

  52. Danielian PS, White R, Lees JA, Parker MG (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025–1933.

    PubMed  CAS  Google Scholar 

  53. Mullis KB, Faloona FA (1987) Specific synthesis of DNA in vitro via a polymerase chain reaction. Methods Enzymol 155:335–351.

    Article  PubMed  CAS  Google Scholar 

  54. Brail L, Fan E, Levin DB, Logan DM (1993) Improved polymerase fidelity in PCR-SSCPA. Mutat Res 303:171–175.

    Article  PubMed  CAS  Google Scholar 

  55. Goodman MR, Creighton S, Bloom LB, Petruska J (1993) Biochemical basis of DNA replication fidelity. Crit Rev Biochem Mol Biol 28:83–126.

    Article  PubMed  CAS  Google Scholar 

  56. Sooknanan R, Howes M, Read L, Malek LT (1994) Fidelity of nucleic acid amplification with avian myeloblastosis virus reverse transcriptase and T7 RNA polymerase. Biotechniques 17:1077–1080, 1083–1085.

    PubMed  CAS  Google Scholar 

  57. Bakhanashvili M, Hizi A (1992) Fidelity of the RNA-dependent DNA synthesis exhibited by the reverse transcriptases of human immunodeficiency virus types 1 and 2 and of murine leukemia virus; mispair extension frequencies. Biochemistry 31:9393–9398.

    Article  PubMed  CAS  Google Scholar 

  58. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giacoma JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED (1994) CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54:6049–6052.

    PubMed  CAS  Google Scholar 

  59. Sharief Y, Wilson EM, Hall SM, Hamil KG, Tan J-A, French FS, Mohler JL (1995) Adrogen receptor gene mutations associated with prostatic carcinoma. Proc Amer Assoc Cancer Res 36:A160S.

    Google Scholar 

  60. Newmark JR, Hardy DO, Tonb DC (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319–6323.

    Article  PubMed  CAS  Google Scholar 

  61. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759–765.

    Article  PubMed  CAS  Google Scholar 

  62. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 0888–8809:1541–1550.

    Article  Google Scholar 

  63. de Winter JAR, Janssen PJA, Sleddens HMEB, Verleun-Mooijman MCT, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, van der Kwast TH (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735–746.

    Google Scholar 

  64. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (199•) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398.

    Google Scholar 

  65. Quarmby VE, Yarbrough WG, Lubahn DB, French FS, Wilson EM (1990) Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4:22–28.

    Article  PubMed  CAS  Google Scholar 

  66. Kleinerman DI, Troncoso P, Pisters LL, Sleddens HMEB, Navone NM, Ordonez NG, van der Kwast TH, Schroeder FH, Brinkmann AO, Logothetis CJ, Hsieh J-T, von Eschenbach AC, Trapman J (1994) Evaluation of androgen receptor expression and structure in bone metastases of prostate carcinoma. Basic Clin Aspects Prostate Cancer A-22.

    Google Scholar 

  67. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger J, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864.

    PubMed  CAS  Google Scholar 

  68. Tilley WD, Buchanan G, Hickey TE, Horsfall DJ (1995) Detection of androgen receptor mutations in human prostate cancers by immunohistochemistry and SSCP. Proc Am Assoc Cancer Res 36:abstract 1586.

    Google Scholar 

  69. Tilley WD, Buchanan G, Hickey TE, Bentel JM (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277–285.

    PubMed  CAS  Google Scholar 

  70. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM (1994) Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res 54:4096–4102.

    PubMed  CAS  Google Scholar 

  71. Marcelli M, Tilley WD, Wilson CM (1990) A single nucleotide substitution introduces a premature termination codon into the androgen receptor gene of a patient with receptor-negative androgen resistance. J Clin Invest 85:1522–1528.

    Article  PubMed  CAS  Google Scholar 

  72. Takahashi H, Furusato M, Allsbrook WC, Nishii H, Wakui S, Barrett JC, Boyd J (1995) Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 55:1621–1624.

    PubMed  CAS  Google Scholar 

  73. Sultan C, Lumbroso S, Poujol N, Belon C, Boudon C, Lobaccaro JM (1993) Mutations of androgen receptor gene in androgen insensitivity syndromes. J Steroid Biochem Mol Biol 46:519–530.

    Article  PubMed  CAS  Google Scholar 

  74. Hiipakka RA, Liao S (1995) Androgen receptors and action. In L DeGroot, ed. Endocrinology. Philadelphia: WB Saunders, pp 2336–2350.

    Google Scholar 

  75. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 9:401–406.

    Article  PubMed  CAS  Google Scholar 

  76. La Spada AR, Wilson EM, Lubahn DB (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79.

    Article  PubMed  Google Scholar 

  77. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER (1994) Microsatellite mutation (CAG24-18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74–80.

    Article  PubMed  CAS  Google Scholar 

  78. Irvine RA, Yu MC, Ross RK, Coetzee GA (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937–1940.

    PubMed  CAS  Google Scholar 

  79. Scher H, Hardy DO, Bogenreider T, Amsterdam A, Frank S, Zhang Z-F, Catterall J, Nanus D (1995) Androgen receptor CAG repeat length polymorphisms in patients with prostatic cancer: Association with sensitivity to androgen ablation. Proc Am Soc Clin Oncol 14:abstract 602.

    Google Scholar 

  80. Vogelzang NJ, Schellhammer PF, Block NL, Jones MS, Kennealey GT (1995) A randomized double-blind trial in 813 previously untreated metastatic prostate cancer patients comparing a new antiandrogen Casodex (bicalutamide) with Eulexin (flutamide) in combination with luteinizing hormone releasing hormone analogue therapy. Proc Am Soc Clin Oncol 14:abstract 642.

    Google Scholar 

  81. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE (1994) Surprising activity of flutamide withdrawal when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 86:222–227.

    Article  PubMed  CAS  Google Scholar 

  82. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choykee P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM (1992) Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881–889.

    PubMed  CAS  Google Scholar 

  83. Akazaki K, Stemmerman GN (1973) Comparative study of latent carcinoma of the prostates among Japanese in Japan and Hawaii. J Natl Cancer Inst 50:1137–1144.

    PubMed  CAS  Google Scholar 

  84. Hanenszel W, Kurihari M (1968) Studies of Japanese migrants: Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43–68.

    Google Scholar 

Download references

Authors
  1. Edward P. Gelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

  2. Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

  3. Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Gelmann, E.P. (1996). Androgen Receptor Mutations in Prostate Cancer. In: Hait, W.N. (eds) Drug Resistance. Cancer Treatment and Research, vol 87. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1267-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1267-3_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8540-3

  • Online ISBN: 978-1-4613-1267-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation